Analysis of data collected between March 2020-February 2021 from nearly 2 million Americans indicates patients diagnosed with COVID-19 may be more likely to develop shingles in the six months following
SAN FRANCISCO, March 25, 2022 GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the US Food and Drug Administration has amended the Emergency Use Authorization Fact. | March 25, 2022
US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment by allowing people to start directly with injections For media and investors
A vaccine manufactured in plants and developed in Canada Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted